[Prevention of hepatitis B--analysis of cost-effectiveness after liver transplantation] NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Prevention of hepatitis B--analysis of cost-effectiveness after liver transplantation]

Langenbecks Arch Chir Suppl Kongressbd. 1997;114:1048-50. Unique Identifier : AIDSLINE MED/98235417
Golling M; Arnold JC; Rudek B; Theilmann L; Herfarth C; Otto G; Chirurgische und Medizinische Universitatsklinik Heidelberg.

Abstract: HBV recurrence, despite immunoprophylaxis which occurred in 67% of our patients, remains the main problem following liver transplantation for HBV infection. Pretransplant viral replication (HBV-DNA) and probably viral mutation may account to some degree for the failures involved in hyperimmunoglobulin prophylaxis. In order to improve the cost/benefit relationship, only HBV-DNA and HBeAG-negative patients should be selected or preoperatively seroconverted by nucleosides (famciclovir, lamivudine); post-operatively a variable HIG prophylaxis should be administered.
Keywords: *Antiviral Agents/ADMINISTRATION & DOSAGE *Hepatitis B/PREVENTION & CONTROL *Lamivudine/ADMINISTRATION & DOSAGE *Liver Transplantation/ECONOMICS *Postoperative Complications/PREVENTION & CONTROL *2-Aminopurine/ANALOGS & DERIVATIVESKWDantiviralagents/administration&dosageKWDhepatitisb/prevention&controlKWDlamivudine/administration&dosageKWDlivertransplantation/economicsKWDpostoperativecomplications/prevention&controlKWD2-aminopurine/analogs&derivatives
980830
M9881178

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .